Longitudinal Analysis of Quadriceps Muscle Strength in Patients with Previous COVID-19 Hospitalization and in Patients with Post-Acute Sequelae following Mild COVID-19.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
15 Oct 2022
Historique:
received: 04 08 2022
revised: 11 10 2022
accepted: 13 10 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 29 10 2022
Statut: epublish

Résumé

Muscle weakness is a prominent symptom in post-acute sequelae of COVID-19 (PASC). However, few studies have objectively and longitudinally assessed muscle strength after varying COVID-19 severity grades. This observational study aimed to explore the prevalence, determinants, and 1.5 years change of quadriceps muscle weakness in 98 patients discharged from COVID-19 hospitalization and in 50 patients with PASC following mild COVID-19. Isometric quadriceps maximal voluntary contraction (MVC) was assessed on a computerized dynamometer at three visits. Also, in a subgroup of 14 post-COVID-19 patients with quadriceps muscle weakness, muscle thickness and echo intensity were determined by muscle ultrasound of nine upper and lower extremity muscles. Muscle weakness was found in 59% of post-hospitalized patients and in 65% of those with PASC following mild COVID-19 at ~14 weeks after acute COVID-19. Whereas during ~1.5 years follow-up MVC modestly improved, muscle weakness prevalence remained unchanged. Hospital length of stay and diabetes mellitus were identified as possible predictors of muscle weakness following COVID-19 hospitalization. No predictors could be identified in those with PASC following mild COVID-19. Ultrasound outcomes revealed no large structural abnormalities. In conclusion, clinically relevant muscle weakness is common after COVID-19 and its long-term improvement is poor. Future studies with relevant control groups are warranted to confirm our data.

Identifiants

pubmed: 36297002
pii: nu14204319
doi: 10.3390/nu14204319
pmc: PMC9608500
pii:
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Ann Neurol. 2017 May;81(5):633-640
pubmed: 28241384
Eur J Neurol. 2022 Sep;29(9):2832-2841
pubmed: 35661354
Nat Commun. 2022 Jul 21;13(1):4213
pubmed: 35864108
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Muscle Nerve. 2020 Jun;61(6):783-788
pubmed: 32239702
PLoS One. 2019 Jan 4;14(1):e0210186
pubmed: 30608987
Support Care Cancer. 2016 Sep;24(9):3883-7
pubmed: 27095352
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049168
Neurology. 2020 Apr 7;94(14):e1488-e1494
pubmed: 32132178
J Psychosom Res. 1994 Jul;38(5):383-92
pubmed: 7965927
Diabetes. 2006 Jun;55(6):1813-8
pubmed: 16731847
ERJ Open Res. 2022 Apr 11;8(2):
pubmed: 35415186
Lancet Reg Health West Pac. 2021 Jul;12:100193
pubmed: 34189493
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
Chron Respir Dis. 2019 Jan-Dec;16:1479973118816497
pubmed: 30789016
Age Ageing. 2021 Nov 10;50(6):2222-2229
pubmed: 34657960
Eur J Clin Nutr. 1997 Aug;51(8):495-503
pubmed: 11248873
Muscle Nerve. 2022 Aug;66(2):197-202
pubmed: 35583147
Can J Neurol Sci. 2018 Sep;45(5):504-515
pubmed: 30234472
Chest. 1988 Mar;93(3):580-6
pubmed: 3342669
J Clin Epidemiol. 1998 Nov;51(11):1055-68
pubmed: 9817123
Scand J Med Sci Sports. 2021 Dec;31(12):2249-2258
pubmed: 34551157
J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1136-1143
pubmed: 34363345
Muscle Nerve. 2022 Oct;66(4):453-461
pubmed: 35859342
Muscle Nerve. 2021 Apr;63(4):455-466
pubmed: 33051891
Neurohospitalist. 2017 Jan;7(1):41-48
pubmed: 28042370
Eur Radiol. 2020 Sep;30(9):4903-4909
pubmed: 32314058
Eur J Appl Physiol. 2012 Jan;112(1):267-75
pubmed: 21537927
J Am Geriatr Soc. 2009 Aug;57(8):1411-9
pubmed: 19682143
J Infect Dis. 2022 Apr 16;:
pubmed: 35429399
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):11-22
pubmed: 34997689
J Am Med Dir Assoc. 2014 Jun;15(6):448.e1-6
pubmed: 24755478
J Endocrinol. 2008 Apr;197(1):1-10
pubmed: 18372227
Intensive Care Med. 2007 Nov;33(11):1876-91
pubmed: 17639340
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540

Auteurs

Anouk A F Stoffels (AAF)

Department of Pulmonary Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Esther L van Voorthuizen (EL)

Department of Pulmonary Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Hieronymus W H van Hees (HWH)

Department of Pulmonary Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Jeannette B Peters (JB)

Department of Pulmonary Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Hanneke A C van Helvoort (HAC)

Department of Pulmonary Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Nicol C Voermans (NC)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Jonne Doorduin (J)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Bram van den Borst (B)

Department of Pulmonary Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH